Thus, aggressive HG bladder cancers are characterized by elevated NUAK2 expression and YAP/TAZ activity, and either blocking expression or pharmacologically inhibiting NUAK2 is effective in restoring Hippo pathway activity and attenuating cell growth. The gene discussed is NUAK2; the disease is urinary bladder carcinoma.